| Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy CM Diaz-Montero, ML Salem, MI Nishimura, E Garrett-Mayer, DJ Cole, ... Cancer immunology, immunotherapy 58, 49-59, 2009 | 1537 | 2009 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246-3256, 2022 | 488 | 2022 |
| A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells S Solito, E Falisi, CM Diaz-Montero, A Doni, L Pinton, A Rosato, ... Blood, The Journal of the American Society of Hematology 118 (8), 2254-2265, 2011 | 398 | 2011 |
| Docetaxel for treatment of solid tumours: a systematic review of clinical data A Montero, F Fossella, G Hortobagyi, V Valero The lancet oncology 6 (4), 229-239, 2005 | 379 | 2005 |
| Molecular profiling for breast cancer: a comprehensive review M Kittaneh, AJ Montero, S Glück Biomarkers in cancer 5, BIC. S9455, 2013 | 285 | 2013 |
| Myeloid-derived suppressor cells in cancer patients: a clinical perspective AJ Montero, CM Diaz-Montero, CE Kyriakopoulos, V Bronte, ... Journal of immunotherapy 35 (2), 107-115, 2012 | 261 | 2012 |
| Cellular redox pathways as a therapeutic target in the treatment of cancer AJ Montero, J Jassem Drugs 71, 1385-1396, 2011 | 238 | 2011 |
| Treating breast cancer in the 21st century: emerging biological therapies G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero Journal of Cancer 4 (2), 117, 2013 | 232 | 2013 |
| Novel HER2–targeted therapies for HER2–positive metastatic breast cancer S Kunte, J Abraham, AJ Montero Cancer 126 (19), 4278-4288, 2020 | 198 | 2020 |
| Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications CM Diaz-Montero, J Finke, AJ Montero Seminars in oncology 41 (2), 174-184, 2014 | 194 | 2014 |
| A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer V Diaby, R Tawk, V Sanogo, H Xiao, AJ Montero Breast cancer research and treatment 151, 27-40, 2015 | 164 | 2015 |
| A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer PJ Hosein, G de Lima Lopes Jr, VH Pastorini, C Gomez, J Macintyre, ... American journal of clinical oncology 36 (2), 151-156, 2013 | 142 | 2013 |
| Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial V Diaby, G Adunlin, AJ Montero Pharmacoeconomics 32, 101-108, 2014 | 133 | 2014 |
| Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in … ML Salem, CM Díaz-Montero, AA Al-Khami, SA El-Naggar, O Naga, ... The Journal of Immunology 182 (4), 2030-2040, 2009 | 133 | 2009 |
| Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II … AJ Montero, CM Diaz-Montero, YE Deutsch, J Hurley, LG Koniaris, ... Breast cancer research and treatment 132, 215-223, 2012 | 129 | 2012 |
| Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma CG Kohn, SB Zeichner, Q Chen, AJ Montero, DA Goldstein, CR Flowers Journal of Clinical Oncology 35 (11), 1194-1202, 2017 | 116 | 2017 |
| Bevacizumab in the treatment of metastatic breast cancer: friend or foe? AJ Montero, M Escobar, G Lopes, S Glück, C Vogel Current oncology reports 14, 1-11, 2012 | 114 | 2012 |
| Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer A phase 1 trial AJ Ocean, KL Pennington, MJ Guarino, A Sheikh, T Bekaii‐Saab, ... Cancer 118 (22), 5497-5506, 2012 | 108 | 2012 |
| Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer SB Zeichner, T Koru-Sengul, N Shah, Q Liu, NJ Markward, AJ Montero, ... Clinical breast cancer 15 (1), e1-e11, 2015 | 107 | 2015 |
| Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin–agarose pulldown assay WG Deng, Y Zhu, A Montero, KK Wu Analytical biochemistry 323 (1), 12-18, 2003 | 99 | 2003 |
Elizabeth Garrett-MayerAmerican Society of Clinical OncologyVerified email at asco.org
